Site Search

The patient-centered outcomes research (PCOR) training manual provides discrete steps, tools, and resources that CF Center research teams can take to integrate and maintain patient/caregiver-partners in CF research.

The Cystic Fibrosis Foundation is requesting applications with a Letter of Intent for innovative, multi-site quality improvement projects that aim to test tools and processes facilitating remote cystic fibrosis care delivery. 

This program is intended to facilitate research that will contribute to the development of new therapies or therapeutic strategies to treat cystic fibrosis with an emphasis on advancing CFTR gene repair and replacement approaches.
 

Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2

The Cystic Fibrosis Foundation is requesting letters of intent for research projects that aim to use available clinical trials in organ transplantation specimens and/or clinical data to improve knowledge of chronic lung allograft dysfunction pathogenesis and explore new approaches to detection, prevention, monitoring, or treatment of chronic lung allograft dysfunction.
 

The Idea Development Award is intended to support work that leads to sufficient project development to enable an application for future research funding from the Cystic Fibrosis Foundation or the National Institutes of Health. 

With a record 45 clinical trials either ongoing or starting up in 2016, research coordinators and principal investigators throughout the Therapeutics Development Network took time out in San Antonio recently to discuss clinical research and put attendees through boot camp.

Hear from John P. Clancy, M.D., the first plenary speaker at this year's NACFC, about recent advances in personalized medicine, which could allow clinicians to better tailor treatment to the individual with CF. 

The Foundation hosted a small conference that brought together CF scientists, clinical researchers, and biotechnology and pharmaceutical industry representatives. Learn more and watch a short video of attendees sharing their thoughts about the progress we are making in CF research.

PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.